Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Research

ART1 knockdown decreases the IL-6-induced proliferation of colorectal cancer cells

Authors: Ting Lin, Shuxian Zhang, Yi Tang, Ming Xiao, Ming Li, Hanjuan Gong, Hailun Xie, Yalan Wang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Colorectal cancer (CRC) is a worldwide health concern. Chronic inflammation is a risk factor for CRC, and interleukin-6 (IL-6) plays a pivotal role in this process. Arginine-specific mono-ADP-ribosyltransferase-1 (ART1) positively regulates inflammatory cytokines. ART1 knockdown reduces the level of glycoprotein 130 (gp130), a key transducer in the IL-6 signalling pathway. However, the relationship between ART1 and IL-6 and the resulting effects on IL-6-induced proliferation in CRC cells remain unclear. The aims of this study were to investigate the effects of ART1 knockdown on IL-6-induced cell proliferation in vitro and use an in vivo murine model to observe the growth of transplanted tumours. The results showed that compared with the control, ART1-sh cancer cells induced by IL-6 exhibited reduced viability, a lower rate of colony formation, less DNA synthesis, decreased protein levels of gp130, c-Myc, cyclin D1, Bcl-xL, and a reduced p-STAT3/STAT3 ratio (P < 0.05). Moreover, mice transplanted with ART1-sh CT26 cells that had high levels of IL-6 displayed tumours with smaller volumes (P < 0.05). ART1 and gp130 were colocalized in CT26, LoVo and HCT116 cells, and their expression was positively correlated in human CRC tissues. Overall, ART1 may serve as a promising regulatory factor for IL-6 signalling and a potential therapeutic target for human CRC.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394–424.CrossRef
2.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.PubMedCrossRef
3.
Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet (London England). 2005;365:153–65.PubMedCrossRef
4.
Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer. Semin Immunol. 2017;32:43–53.PubMedCrossRef
5.
Tabung FK, Liu L, Wang W, Fung TT, Wu K, Smith-Warner SA, Cao Y, Hu FB, Ogino S, Fuchs CS, Giovannucci EL. Association of Dietary Inflammatory potential with Colorectal Cancer Risk in men and women. JAMA Oncol. 2018;4:366–73.PubMedPubMedCentralCrossRef
6.
Zeng J, Tang ZH, Liu S, Guo SS. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017;23:1780–6.PubMedPubMedCentralCrossRef
7.
Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K, Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998;22:895–8.PubMedCrossRef
8.
Chung Y, Chang Y. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83:222–6.PubMedCrossRef
9.
Taher M, Davies D, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans. 2018;46:1449–62.PubMedCrossRef
10.
11.
Heinrich P, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297–314.PubMedPubMedCentralCrossRef
12.
Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013;17:1303–28.PubMedCrossRef
13.
Laing S, Unger M, Koch-Nolte F, Haag F. ADP-ribosylation of arginine. Amino Acids. 2011;41:257–69.PubMedCrossRef
14.
Fabrizio G, Paola SD, Stilla A, Giannotta M, Ruggiero C, Menzel S, Koch-Nolte F, Sallese M, Girolamo MD. ARTC1-mediated ADP-ribosylation of GRP78/BiP: a new player in endoplasmic-reticulum stress responses. Volume 72. Cellular and molecular life sciences: CMLS; 2015. pp. 1209–25.
15.
Corda D, Di Girolamo M. Mono-ADP-ribosylation: a tool for modulating immune response and cell signaling. Science’s STKE: signal transduction knowledge environment 2002, 2002: pe53.
16.
17.
Del-Vecchio M, Balducci E. Mono ADP-ribosylation inhibitors prevent inflammatory cytokine release in alveolar epithelial cells. Mol Cell Biochem. 2008;310:77–83.PubMedCrossRef
18.
Picchianti M, Russo C, Castagnini M, Biagini M, Soldaini E, Balducci E. NAD-dependent ADP-ribosylation of the human antimicrobial and immune-modulatory peptide LL-37 by ADP-ribosyltransferase-1. Innate Immun. 2015;21:314–21.PubMedCrossRef
19.
Tang Y, Wang Y, Yang L, Xu J, Xiong W, Xiao M, Li M. Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma. Int J Mol Med. 2013;32:130–6.PubMedCrossRef
20.
Xiao M, Tang Y, Chen W, Wang Y, Yang L, Li X, Song GL, Kuang J. Tubb3 regulation by the Erk and Akt signaling pathways: a mechanism involved in the effect of arginine ADP-ribosyltransferase 1 (Art1) on apoptosis of colon carcinoma CT26 cells. Tumour Biology: J Int Soc Oncodevelopmental Biology Med. 2016;37:2353–63.CrossRef
21.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.PubMedCrossRef
22.
B.Fromowitz F, V.Viola M, Chao S, Oravez S, Mishriki Y, Finkel G. Grimson R and Lundy J: Ras p21 expression in the progression of breast cancer. Hum Pathol. 1987;18:1268–75.CrossRef
23.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef
24.
Hoffmann M, Schwertassek U, Seydel A, Weber K, Falk W, Hauschildt S, Lehmann. Jr: a refined and translationally relevant model of chronic DSS colitis in BALB/c mice. Lab Anim. 2018;52:240–52.PubMedCrossRef
25.
Diehl K, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal J, van de Vorstenbosch C. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicology: JAT. 2001;21:15–23.CrossRef
26.
Lee C, Park K, Lim S, Park J, Chung W. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull. 2007;30:2191–5.PubMedCrossRef
27.
Bonito NA, Drechsler J, Stoecker S, Carmo CR, Seckl MJ, Hermanns HM, Costa-Pereira AP. Control of gp130 expression by the mitogen-activated protein kinase ERK2. Oncogene. 2014;33:2255–63.PubMedCrossRef
28.
Waetzig GH, Chalaris A, Rosenstiel P, Suthaus J, Holland C, Karl N, Uriarte LV, Till A, Scheller J, Grötzinger J, Schreiber S, Rose-John S, Seegert D. N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem. 2010;285:1781–9.PubMedCrossRef
29.
Liu X, Wei W, Li X, Shen P, Ju D, Wang Z, Zhang R, Yang F, Chen C, Cao K, Zhu G, Chen H, Chen L, Sui J, Zhang E, Wu K, Wang F, Zhao L, Xi R. BMI1 and MEL18 promote colitis-Associated Cancer in mice via REG3B and STAT3. Gastroenterology. 2017;153:1607–20.PubMedCrossRef
30.
Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, Vita FD. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol (Orlando Fla). 2002;102:169–78.CrossRef
31.
Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151:31–8.PubMedCrossRef
32.
Li J, Xu J, Yan X, Jin K, Li W, Zhang R. Targeting Interleukin-6 (IL-6) sensitizes Anti-PD-L1 treatment in a Colorectal Cancer Preclinical Model. Med Sci Monitor: Int Med J Experimental Clin Res. 2018;24:5501–8.CrossRef
33.
Uciechowski P, Dempke W. Interleukin-6: a masterplayer in the Cytokine Network. Oncology. 2020;98:131–7.PubMedCrossRef
34.
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, Laethem J-L, Ottensmeier C, Lopez-Martin JA, Sally Clive FJ, Ray-Coquard I, Dirix L, Machiels J-P, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, Velde Hvd, Tromp B, Vermeulen J, Kurzrock R. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin cancer Research: Official J Am Association Cancer Res. 2014;20:2192–204.CrossRef
35.
Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82.PubMedCrossRef
36.
Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, Yang J, Zhang Z, Ji Z. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis: Int J Program cell Death. 2018;23:356–74.CrossRef
37.
Liu F, Jin H, Shen J, Wu D, Tian Y, Huang C. Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy. Biochem Biophys Res Commun. 2019;519:572–8.PubMedCrossRef
38.
Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. British journal of pharmacology 2008: S414-427.
39.
Fasnacht N, Müller W. Conditional gp130 deficient mouse mutants. Semin Cell Dev Biol. 2008;19:379–84.PubMedCrossRef
40.
Zolkiewska A, Moss J. Integrin alpha 7 as substrate for a glycosylphosphatidylinositol-anchored ADP-ribosyltransferase on the surface of skeletal muscle cells. J Biol Chem. 1993;268:25273–6.PubMedCrossRef
41.
42.
Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005;58:833–8.PubMedPubMedCentralCrossRef
43.
Shi Y, Zhou W, Cheng L, Chen C, Huang Z, Fang X, Wu Q, He Z, Xu S, Lathia JD, Ping Y, Rich JN, Bian X-W, Bao S. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. Cell Death Differ. 2017;24:167–80.PubMedCrossRef
44.
Wei J, Ma L, Lai Y-H, Zhang R, Li H, Li C, Lin J. Bazedoxifene as a novel GP130 inhibitor for Colon cancer therapy. J Experimental Clin cancer Research: CR. 2019;38:63.PubMedCentralCrossRef
45.
Qin M, Long F, Wu W, Yang D, Huang M, Xiao C, Chen X, Liu X, Zhu Y. Hydrogen sulfide protects against DSS-induced colitis by inhibiting NLRP3 inflammasome. Free radical biology & medicine 2019, 137: 99–109.
46.
Su Y, Guan X-Q, Liu F-Q, Wang Y-L. The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells. Int J Mol Med. 2014;34:842–8.PubMedCrossRef
47.
Girolamo MD, Fabrizio G. Overview of the mammalian ADP-ribosyl-transferases clostridia toxin-like (ARTCs) family. Biochem Pharmacol. 2019;167:86–96.PubMedCrossRef
48.
Xu J, Xiong W, Zeng Z, Tang Y, Wang YL, Xiao M, Li M, Li QS, Song GL, Kuang J. Effect of ART1 on the proliferation and migration of mouse colon carcinoma CT26 cells in vivo. Mol Med Rep. 2017;15:1222–8.PubMedPubMedCentralCrossRef
49.
Song G-L, Jin C-C, Zhao W, Tang Y, Wang Y-L, Li i, Xiao M, Li X, Li Q-S, Lin X, Chen W-W, Kuang J. Regulation of the RhoA/ROCK/AKT/β-catenin pathway by arginine-specific ADP-ribosytransferases 1 promotes migration and epithelial-mesenchymal transition in colon carcinoma. Int J Oncol. 2016;49:646–56.PubMedCrossRef
50.
Yang L, Xiao M, Li X, Tang Y, Wang Y. Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway. Int J Mol Med. 2016;37:734–42.PubMedPubMedCentralCrossRef
51.
Leutert M, Menzel S, Braren R, Rissiek B, Hopp A, Nowak K, Bisceglie L, Gehrig P, Li H, Zolkiewska A, Koch-Nolte F, Hottiger M. Proteomic characterization of the heart and skeletal muscle reveals widespread arginine ADP-Ribosylation by the ARTC1 Ectoenzyme. Cell Rep. 2018;24:1916–29. e1915.PubMedCrossRef
52.
Kane A, Thorpe M, Morse M, Howard B, Oldan J, Zhu J, Wong T, Petry N, Reiman R, Borges-Neto S. Predictors of Survival in 211 patients with Stage IV Pulmonary and gastroenteropancreatic MIBG-Positive neuroendocrine tumors treated with I-MIBG. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2018;59:1708–13.CrossRef
Metadata
Title
ART1 knockdown decreases the IL-6-induced proliferation of colorectal cancer cells
Authors
Ting Lin
Shuxian Zhang
Yi Tang
Ming Xiao
Ming Li
Hanjuan Gong
Hailun Xie
Yalan Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12120-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival

Research

Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Study Protocol

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Research

Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation

Research

Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival

Research

Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits